- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03012087
Using m-Health Tools to Reduce the Misuse of Opioid Pain Relievers
21. august 2017 opdateret af: Johns Hopkins Bloomberg School of Public Health
The aim of this study is to pilot test a web-based, patient-centered educational program that encourages the patient to have an informed discussion about pain medication options with their emergency department (ED) provider.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This multi-site, randomized trial will evaluate an m-health program designed to aid the patient in making an informed decision about their pain treatment.
Patients reporting to the ED with an injury-related chief complaint who agree to participate are randomized to receive the intervention program, My Healthy Choices, or an attention-matched control.
My Healthy Choices pairs tailored education with a patient decision aid to describe what opioid and non-opioid pain medications are, assess the patient's risk factors for opioid-related adverse effects, and produce a tailored report that patients are encouraged to share with their doctor.
Data are collected through surveys at three time points during the ED encounter (baseline, immediately after the intervention, and just before discharge), and at a 6-week follow-up survey.
The primary outcomes are whether the patient prefers an opioid pain reliever (OPR) and whether the patient takes an OPR.
The investigators hope this program will facilitate patient-provider communication, as well as reduce the number of prescriptions written for OPRs and thus the number of patients exposed to prescription opioids and the associated risks of addiction and overdose.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
123
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21205
- Johns Hopkins Hospital Emergency Department
-
-
West Virginia
-
Morgantown, West Virginia, Forenede Stater, 26506
- West Virginia University Emergency Department
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- ED visit for an injury- or pain-related chief complaint
- 18 years of age or older
- speak English
- has a smart phone or email address that is used on a regular basis
- no previous medical care for the current complaint
- triage pain score between 7-10
Exclusion Criteria:
- allergy to pain medications
- have used a prescription pain medication for more than two days in the past month
- report renal problems or a history of dialysis
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Intervention Group
MyHealthyChoices
|
My Healthy Choices explains what opioid pain medications are, assesses and explains the patient's risk factors related to taking opioids, assesses patient preferences about pain medications, and produces a tailored patient report based on the answers.
The patient is encouraged to show the report to the treating ED clinician so they can discuss medication options for treating the patient's pain.
Following discharge from the ED, intervention group participants discharged with a prescription pain reliever receive messages about safe medication use, storage, and disposal and access to an educational web portal that contains more information on prescription pain medications and safety.
|
|
Placebo komparator: Control Group
Health Risk Assessment
|
The WellSource health risk assessment content focuses on general health promotion, and the participant's overall health and wellness.
A summary report based on the participants' answers is sent to their email address.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Self-Reported Preference for Opioid Pain Reliever
Tidsramme: Baseline and Immediate Post-test
|
Assessed via questionnaire on a scale of 0-10.
|
Baseline and Immediate Post-test
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Knowledge about Prescription Pain Medication Side Effects and Safe Practices for Taking, Storing and Disposing Prescription Pain Medications
Tidsramme: Baseline and 6 weeks
|
Assessed with a 25-item questionnaire.
Knowledge items will be scored correct or incorrect and summed to generate a total knowledge score.
|
Baseline and 6 weeks
|
|
Self-Reported Prescription Drug Storage and Disposal Behaviors
Tidsramme: 6 weeks
|
Assessed via 5 items on a questionnaire.
Behaviors will be scored correct or incorrect and tabulated across study groups.
|
6 weeks
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Andrea C Gielen, ScD ScM, Johns Hopkins Bloomberg School of Public Health
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
1. september 2016
Primær færdiggørelse (Faktiske)
1. april 2017
Studieafslutning (Faktiske)
1. juni 2017
Datoer for studieregistrering
Først indsendt
13. december 2016
Først indsendt, der opfyldte QC-kriterier
4. januar 2017
Først opslået (Skøn)
6. januar 2017
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
22. august 2017
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
21. august 2017
Sidst verificeret
1. august 2017
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- MyHealthyChoices
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Misbrug af receptpligtig medicin
-
Onconic Therapeutics Inc.Rekruttering
-
Seoul National University Bundang HospitalAktiv, ikke rekrutterendeDrug Drug Interaction (DDI)Sydkorea
-
Theravance BiopharmaAfsluttet
-
Beijing Union Pharmaceutical Factory LtdIkke rekrutterer endnuDrug Drug Interaction (DDI)Kina
-
SPARK BiopharmaAfsluttetDrug Drug Interaction (DDI)Sydkorea
-
Allyx TherapeuticsNational Institute on Aging (NIA)Aktiv, ikke rekrutterendeDrug Drug Interaction (DDI)Forenede Stater
-
Astellas Pharma Europe B.V.AfsluttetSunde emner | Drug-Drug Interaction (DDI)Det Forenede Kongerige
-
Astellas Pharma Europe B.V.AfsluttetSunde emner | Farmakokinetik | Drug-Drug Interaction (DDI)Tyskland
-
Astellas Pharma Europe B.V.AfsluttetSunde emner | Farmakokinetik | Drug-Drug Interaction (DDI)Tyskland
-
Astellas Pharma Europe B.V.AfsluttetSunde emner | Drug-Drug Interaction (DDI)Frankrig